A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT ID: NCT06124807
Last Updated: 2025-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
179 participants
INTERVENTIONAL
2023-11-17
2025-07-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06230523
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06683508
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
NCT04881760
A Study of LY3305677 in Participants With Obesity Or Overweight
NCT05623839
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
NCT05051579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY3305677 Dose 1
Participants will receive LY3305677 subcutaneously (SC).
LY3305677
Administered SC
LY3305677 Dose 2
Participants will receive LY3305677 SC.
LY3305677
Administered SC
LY3305677 Dose 3
Participants will receive LY3305677 SC.
LY3305677
Administered SC
Placebo
Participants will receive LY3305677 matching placebo.
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3305677
Administered SC
Placebo
Administered SC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are males and females who agree to abide by the reproductive and contraceptive requirements
W8M-MC-CWMM:
* Have a BMI ≥27 kilograms per square meter (kg/m²)
Exclusion Criteria
* Have any prior diagnosis of diabetes mellitus, that is type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus, except gestational diabetes.
* Have any of the following cardiovascular conditions within 6 months prior to screening:
* acute myocardial infarction
* cerebrovascular accident (stroke)
* unstable angina, or
* hospitalization due to congestive heart failure (CHF).
* Have a history of acute or chronic pancreatitis.
* Have a history of New York Heart Association (NYHA) Functional Classification I-IV CHF.
* Participants with hypertension who do not have well-controlled blood pressure (BP) (\>140/90 mmHg), regardless of antihypertensive treatment. Participants receiving treatment for hypertension should be on a stable antihypertensive regimen for at least 3 months prior to screening.
Note: If the investigator anticipates a need to add antihypertensive medication during the study, the participant should not be included in the ambulatory blood pressure monitoring (ABPM) procedures.
CWMM:
* Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening.
* Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
* Have poorly controlled hypertension.
* Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
* Have a history of symptomatic gallbladder disease within the past 2 years.
* Have a lifetime history of suicide attempts.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, United States
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona, United States
Velocity Clinical Research, Huntington Park
Huntington Park, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Northeast Research Institute (NERI)
Fleming Island, Florida, United States
Suncoast Clinical Research, Inc.
New Port Richey, Florida, United States
Charter Research - Winter Park
Orlando, Florida, United States
Charter Research - Lady Lake
The Villages, Florida, United States
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, United States
Great Lakes Clinical Trials - Andersonville
Chicago, Illinois, United States
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, United States
L-MARC Research Center
Louisville, Kentucky, United States
Knownwell
Needham, Massachusetts, United States
StudyMetrix Research
City of Saint Peters, Missouri, United States
Las Vegas Medical Research
Las Vegas, Nevada, United States
Dent Neurologic Institute
Amherst, New York, United States
North Suffolk Neurology
Port Jefferson Station, New York, United States
Lucas Research, Inc.
New Bern, North Carolina, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
Quality Medical Research
Nashville, Tennessee, United States
IMA Clinical Research Austin
Austin, Texas, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
PlanIt Research, PLLC
Houston, Texas, United States
Tekton Research - Fredericksburg Road
San Antonio, Texas, United States
Spectrum Medical, Inc.
Danville, Virginia, United States
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
W8M-MC-OXA1
Identifier Type: OTHER
Identifier Source: secondary_id
CWMM Master Protocol
Identifier Type: OTHER
Identifier Source: secondary_id
2022-502816-35-00
Identifier Type: OTHER
Identifier Source: secondary_id
18661
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.